Sir, Response to 'Bevacizumab and type 1 idiopathic macular telangiectasia'
We thank Koay et al 1 for their interest in our paper 2 and for presenting an interesting case. We feel that the effectiveness of intravitreal bevacizumab varies among patients with idiopathic macular telangiectasia (MacTel) type 1. In our patients, visual acuity improved only in one of the five eyes at 12 months after the initial treatment. However, Gamulescu et al 3 reported that a single intravitreal bevacizumab markedly increased the visual acuity in a MacTel type 1 patient, and Koay et al 1 showed a case of MacTel type 1 successfully treated with intravitreal bevacizumab.
One possible reason for this discrepancy may be the different treatment protocol. In our study, the protocol was as follows: all patients were examined for changes in the visual acuity or retinal thickness 2 weeks after treatment; if macular oedema did not reduce, additional treatments were performed one to two times at the discretion of the physician at 4-week intervals. In contrast, Koay et al 1 administered a monthly injection of intravitreal bevacizumab three times from the baseline. Thus, a prospective study using a fixed protocol in a larger number of patients is necessary to confirm the efficacy of bevacizumab for the treatment of MacTel type 1.
Recently, He et al 4 reported that Coats' disease is associated with an increased intraocular vascular endothelial growth factor (VEGF) level. In their study, intraocular fluid was obtained from three children and one adult diagnosed with Coats' disease. Currently, this disorder is considered as Coats' disease in childhood and is usually referred to as MacTel type 1 when it is diagnosed in an adult, and involves the macula. Further studies on intraocular VEGF level in MacTel type 1 or adult-onset Coats' disease will show whether VEGF has a function in the pathogenesis of MacTel type1. 1 We report a case of presumed ocular toxicity and significant visual loss in a patient with chronic hepatitis B infection treated with entecavir.
Case report
A 54-year-old Vietnamese male developed reduced vision sequentially in both eyes over a 2-year period. Past medical history included type 2 diabetes mellitus and chronic hepatitis B. In June 2007, the visual acuity (VA) was 6/9 in both eyes, with mild non-proliferative diabetic retinopathy, and no signs of macular abnormalities. During 2008, the VA worsened to hand movements in the right eye, secondary to subretinal fibrotic bands, tractional macular oedema, and diffuse retinal pigment epithelium (RPE) atrophy ( Figure 1a ). Fundus fluorescein angiography (FFA) showed abnormal RPE and foveal ischaemia (Figure 1b) . At the time, the macular oedema was attributed to tractional elevation from the subretinal bands. Although the visual prognosis was guarded, the patient elected to proceed with rightsided pars plana vitrectomy and removal of subretinal bands to alleviate the macular oedema. The surgery was uncomplicated, although the vision did not improve significantly. Following surgery, Fourier-domain optical coherence tomography (FD-OCT) demonstrated reduction in macular oedema, with diffuse outer retinal atrophy, RPE thickening, and subretinal fluid at the fovea (Figure 1c ). All infectious, inflammatory, and autoimmune serological tests were negative.
The patient re-attended in September 2010, with severe left-sided maculopathy and VA 6/48 (Figure 2a ). There were no ocular signs of intraocular uveitis or diabetic complications. Indocyanine green angiography was normal. Widefield Optos (Optos, Dunfermline, Scotland) FFA showed loss of the foveal capillary ring and RPE atrophy, confirmed by fundus autofluorescence (Figures 2b and c) . FD-OCT demonstrated progressive outer retinal degeneration and exudation (Figure 2d) , with features similar to chloroquine-associated retinal toxicity. 2 Visual evoked potentials ( Figure 2e ) were attenuated with pattern electroretinograms extinguished in both eyes (Figure 2f and g ). Ganzfield electroretinograms were delayed and electro-oculograms subnormal in both eyes.
Under the care of the Infectious Diseases Team, in the last 2 years, there were no positive serological tests for vasculitis, sarcoid, human immunodefiency virus, or syhilis, and inflammatory markers were not elevated. On entecavir therapy, the hepatitis B viral load reduced significantly and remained in remission over the previous 18 months. The Manchester uveitis specialist reviewed the case, and no signs of intraocular inflammation presented over the course, and no underlying inflammatory cause was detected from investigations. There was no family history of eye disease, and there were no symptoms of colour vision problems, nyctalopia, photophobia, or distortion, to suggest an inherited retinopathy.
Drug-induced toxicity was not suspected until 2010. The entecavir was first started in 2008 for 4 weeks, and was temporally associated with the right macular oedema and subretinal bands. Entecavir was restarted between August 2009 and 2010, and coincided temporally with the left-sided maculopathy and visual deterioration. The anti-hepatitis treatment was switched to a different class of drug to prevent any further toxicity; however, after 4 months, VA was perception of light OD and 6/48 OS. The FD-OCT features were unchanged, and the patient registered partial-sighted.
Comment
There was a single report of macular oedema in the literature associated with ETV-027/901 clinical trials (n ¼ 1/99); however, this serious adverse event was not deemed related to entecavir treatment. 3 To our knowledge, this is the first report of ocular toxicity presumed secondary to systemic entecavir drug therapy. There were no signs of extraocular drug toxicity in this case. During the course, the non-proliferative diabetic retinopathy consisted of only several scattered intraretinal haemorrhages in the retinal periphery of both eyes. Before the drug toxicity sequentially affecting either eye, the FFA tests did not show any signs of diabetic maculopathy, or any features of foveal vascular zone disruption. These tests excluded the possibility that sub-clinical diabetic disease could have opened up the blood-retinal barrier, for the drug to reach retinal tissue. 
